Arch Therapeutics Obtains Additional Safety Data for Its AC5 Surgical Hemostatic Device(TM) in Successful Preclinical Toxicity Test

Test of AC5(TM) Indicates Systemic Non-Toxicity FRAMINGHAM, MA (Marketwired Jun 9, 2015) Arch Therapeutics, Inc. (OTCQB: ARTH) ( Arch or the Company ), developer of the AC5 Surgical Hemostatic Device™ ( AC5™ ), obtained data from a preclinical toxicity test for AC5™ that show the device was well-tolerated and classified as not toxic in a standardized test of systemic toxicity. The systemic toxicity animal test is a major component of the biocompatibility test panel that a medical device must typically complete successfully prior to use in humans. Testing was conducted under the guidelines provided by the International Organization for Standardization s (ISO) and the study also complied with Good Laboratory Practice (GLP), a Federal regulation (21 CFR part 58) governing the conduct of nonclinical laboratory studies that support or are intended to support applications for research or marketing permits for products regulated by the Food and Drug Administration (FDA). AC5 is a deve


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: